These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21174490)

  • 1. Transiently redirected T cells for adoptive transfer.
    Almåsbak H; Rian E; Hoel HJ; Pulè M; Wälchli S; Kvalheim G; Gaudernack G; Rasmussen AM
    Cytotherapy; 2011 May; 13(5):629-40. PubMed ID: 21174490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
    Xu Y; Zhang M; Ramos CA; Durett A; Liu E; Dakhova O; Liu H; Creighton CJ; Gee AP; Heslop HE; Rooney CM; Savoldo B; Dotti G
    Blood; 2014 Jun; 123(24):3750-9. PubMed ID: 24782509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.
    Choi Y; Yuen C; Maiti SN; Olivares S; Gibbons H; Huls H; Raphael R; Killian TC; Stark DJ; Lee DA; Torikai H; Monticello D; Kelly SS; Kebriaei P; Champlin RE; Biswal SL; Cooper LJ
    Biomed Microdevices; 2010 Oct; 12(5):855-63. PubMed ID: 20574820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
    Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
    Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified process for the production of anti-CD19-CAR-engineered T cells.
    Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
    Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
    Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
    Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
    Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
    Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
    Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
    Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
    Foster JB; Choudhari N; Perazzelli J; Storm J; Hofmann TJ; Jain P; Storm PB; Pardi N; Weissman D; Waanders AJ; Grupp SA; Karikó K; Resnick AC; Barrett DM
    Hum Gene Ther; 2019 Feb; 30(2):168-178. PubMed ID: 30024272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
    Jin C; Fotaki G; Ramachandran M; Nilsson B; Essand M; Yu D
    EMBO Mol Med; 2016 Jul; 8(7):702-11. PubMed ID: 27189167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
    Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
    Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
    Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
    Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.